Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cure-NK
Seongnam-si, Gyeonggi-do, South Koreacure-nk.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cure-NK is a South Korean biotechnology company specializing in the development of next-generation natural killer (NK) cell therapies for the treatment of refractory cancers. The company utilizes a proprietary platform for the high-purity expansion and potent activation of NK cells derived from healthy donors or umbilical cord blood. Their lead programs focus on enhancing the infiltration and persistence of NK cells within the immunosuppressive microenvironment of solid tumors. By leveraging advanced cell engineering and cytokine-based activation, Cure-NK aims to provide off-the-shelf immunotherapy solutions that overcome the limitations of current T-cell based treatments.
- Therapeutic areas
- Oncology
- Modalities
- NK cell therapyCell therapyBiologic
- Industry
- Biotech
02
Partnerships
Hanyang UniversityCatholic University of Korea
Beyond the preview
Go deeper on Cure-NK.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cure-NK.